Stock AnalizRhythm Pharmaceuticals, Inc. RYTM
Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026
Rhythm Pharmaceuticals, Inc. (RYTM) is a healthcare company listed in the US with a market value of about $8.0B. In the twelve months to September 30, 2026 it had revenue of $281M and net income of -$198M, a net margin of -70.6%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -74%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 95% below the current price.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $281M | $190M | $130M | $77M | $24M | $3M | $0 | $0 | $0 | $0 | $0 |
| Net income | -$198M | -$197M | -$261M | -$185M | -$181M | -$70M | -$134M | -$141M | -$74M | -$34M | -$29M |
| Free cash flow | -$83M | -$117M | -$114M | -$136M | -$174M | -$146M | -$122M | -$126M | -$63M | -$30M | -$24M |
| EPS (diluted) | $-2.90 | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 | $-3.04 | $-3.86 | $-2.39 | $-2.83 | $-2.85 |
| Net margin | -70.6% | -103.6% | -200.3% | -238.5% | -766.2% | -2207.1% | — | — | — | — | — |
| ROIC | — | -60.4% | -154.8% | -52.5% | -53.2% | -46.9% | -63.6% | -40.5% | -24.8% | -17.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 17 analysts is $140.12, 22% above the current price; targets range from $112.00 to $168.00; the consensus rating is “Strong buy”; expected EPS is $-4.94 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Rhythm Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 95% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Rhythm Pharmaceuticals pay a dividend?
Not currently.
Is Rhythm Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Rhythm Pharmaceuticals scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.